Strategic Excipient Sourcing: Navigating Supply Chain Resilience, Quality & Sustainability by Design

by Gattefosse; original article first published at Drug Development and Delivery

THE EVOLVING ROLE OF THE EXCIPIENT PARTNER

The pharmaceutical landscape is currently undergoing a pe­riod of profound transformation, driven by the advent of highly complex, incredibly targeted, and often poorly soluble active pharmaceutical ingredients (APIs). As new drug modalities such as proteolysis targeting chimeras (PROTACs) drive a “golden age” of small molecule innovation, and the explosion of GLP-1 ago­nists leads to a renewed, intense interest in oral peptide delivery, the formulation challenges facing drug developers have never been greater. In this environment, the traditional view of excipi­ents as mere inert fillers or “inactive ingredients” is rapidly be­coming obsolete. Today, excipients are foundational components that dictate a drug’s bioavailability, stability, manufacturability, and ultimate clinical success.

However, evaluating an excipient solely on its functional per­formance within a formulation is no longer sufficient. As the in­dustry faces unprecedented geopolitical shifts, lingering post-pandemic logistical vulnerabilities, tightening regulatory oversight, and urgent sustainability imperatives, pharmaceutical companies must rethink how they source these critical materials. The selection of an excipient supplier is now a strategic decision that touches upon supply chain security, corporate social respon­sibility, and overall business continuity.

This article explores the critical considerations drug develop­ers must evaluate when selecting an excipient partner today. By examining the necessity of robust global supply chains, the non-negotiable nature of modern quality compliance, the rising im­portance of “Sustainability by Design,” and the need to support next-generation therapies, we can understand what a true, mod­ern scientific partnership looks like.

MITIGATING RISK THROUGH GLOBAL SUPPLY CHAIN RESILIENCE

For decades, the pharmaceutical industry operated on a highly globalized and often fragmented supply chain model, but recent years have exposed the fragility of this approach. From sudden international shipping bottlenecks to prolonged customs delays and regional manufacturing disruptions, drug manufac­turers have learned the hard way that reliance on a single geo­graphic source for critical raw materials introduces significant risk.

Today, supply chain resilience is a paramount sourcing con­sideration. Innovative contract development and manufacturing organizations (CDMOs) and pharmaceutical companies are ac­tively seeking suppliers who can offer localized supply, manufac­turing redundancy, and geographic proximity to major development hubs. Establishing operations closer to development sites reduces supply risk, strengthens operational resilience, and ensures the real-time collaboration required to bring complex therapies from the bench to the patient.

A prime example of this strategic shift is the inauguration of Gattefossé’s 62,000-square-foot oleochemical manufacturing site in Lufkin, Texas (Figure 1). Built on a 15-acre campus with ample room for future expansion, this facility represents a mon­umental investment in domestic supply chain security for the North American pharmaceutical market. By establishing large-scale, state-of-the-art excipient manufacturing within the United States, Gattefossé can offer its partners reduced lead times, sim­plified logistics, and faster shipping times. Furthermore, domestic sourcing eliminates international customs uncertainty and delays, providing developers with the highly predictable material flow re­quired for both clinical trials and commercial launch.

Crucially, localized manufacturing must be viewed as part of a broader, redundant global network. By operating manufacturing facilities across the Americas, Europe, and Asia, a supplier can ensure true busi­ness continuity. If a disruption occurs in one hemisphere, secondary production capabilities can seamlessly bridge the gap, ensuring that life-saving medicines con­tinue to reach patients without interruption.

QUALITY ASSURANCE & THE SHIFTING REGULATORY LANDSCAPE

In tandem with supply chain reliability, regulatory compliance and uncompromis­ing quality control remain the bedrock of any excipient sourcing strategy. Health au­thorities worldwide are applying increas­ing scrutiny to the raw materials used in drug products. For example, in December 2022, the FDA issued its first warning letter to an excipient-only manufacturer for vio­lations that included failures to conform to current good manufacturing practices (cGMP) and failing to meet compendial standards.¹ This precedent-setting regula­tory action highlights the critical impor­tance of partnering with suppliers who hold themselves to the highest possible quality standards.

When evaluating an excipient partner, developers must look beyond basic certifi­cations and seek out organizations that embrace a culture of continuous quality improvement. Certifications such as EXCi­PACT and ISO 9001 are essential bench­marks that provide independent verification of a supplier’s adherence to stringent GMP guidelines. Furthermore, the complexity of scaling-up specialized excipients requires deep process knowl­edge and exacting controls to ensure batch-to-batch consistency.

Continue reading here at Drud Development and Delivery

Source: Gattefossé ,  artice at Drug Development and Delivery: EXCIPIENTS – Strategic Excipient Sourcing: Navigating Supply Chain Resilience, Quality & Sustainability by Design

REFERENCES

1. Center for Drug Evaluation and Research. DuPont Nutrition USA Inc. – Warning Letter #627211. (2022).
2. Preserving our environment. Gattefossé Preserving our environment ⋅ Gattefossé.
3. Corporate social responsibility. Gattefossé Innovating with care and responsibility ⋅ Gattefossé
4. DiFranco, N. A. Beyond the Capsule: Unlocking the Full Potential of Lipid Excipients in Oral Solid Dosage Forms. (2026).

If you have any questions or need a sample by Gattefossé, please feel free to contact us: